Contraindications : התוויות נגד

4.3   Contraindications
Nifedilong should not be administered to patients with known hypersensitivity to the active substance, or to other dihydropyridines because of the theoretical risk of cross- reactivity, or to any of the excipients listed in sections 4.4 and 6.1.
Nifedilong should not be used in cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina, or during or within one month of a myocardial infarction.
Nifedilong should not be used for the treatment of acute attacks of angina. The safety of Nifedilong in malignant hypertension has not been established.
Nifedilong should not be used for secondary prevention of myocardial infarction.
Owing to the duration of action of the formulation, Nifedilong should not be administered to patients with hepatic impairment.
Nifedilong should not be administered to patients with a history of gastro- intestinal obstruction, oesophageal obstruction, or any degree of decreased lumen diameter of the gastro-intestinal tract.
Nifedilong must not be used in patients with a Kock pouch (ileostomy after proctocolectomy).
Nifedilong is contra-indicated in patients with inflammatory bowel disease or Crohn's disease.
Nifedilong should not be administered concomitantly with rifampicin since effective plasma levels of nifedipine may not be achieved owing to enzyme induction (see section 4.5).